

Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024

<https://marketpublishers.com/r/GB7B377CAF0DEN.html>

Date: May 2024

Pages: 100

Price: US\$ 3,000.00 (Single User License)

ID: GB7B377CAF0DEN

Contents

1. DECIPHERING COMPLICACIES FOR FERROPTOSIS TARGETING THERAPY

1.1 Outline to Ferroptosis Targeting Therapy

1.2 Chronicle & Development of Ferroptosis Targeting Therapy

2. THE CLINICAL NECESSITY FOR FERROPTOSIS TARGETING THERAPY

3. DUAL ROLE OF FERROPTOSIS AS DIAGNOSTIC & PROGNOSTIC BIOMARKER

4. BREAKTHROUGH STRATEGIES FOR FERROPTOSIS MANAGEMENT

4.1 Small Molecules

4.2 Drug Repurposing

4.3 Photodynamic Therapy

4.4 Extracellular Vesicles

5. FERROPTOSIS TARGETING THERAPY BY INDICATIONS: CLINICAL TRENDS & INNOVATIONS

5.1 Cancer

5.2 Autoimmune & Inflammatory Diseases

5.3 Viral Infections

5.4 Nervous system disorders

5.5 Cardiac Diseases

6. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS OVERVIEW

- 6.1 By Phase
- 6.2 By Country
- 6.3 By Company
- 6.4 By Indication
- 6.5 By Priority Status

7. GLOBAL FERROPTOSIS TARGETING THERAPY CLINICAL TRIALS INSIGHT

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase I
- 7.4 Phase II
- 7.5 Phase III

8. GLOBAL FERROPTOSIS TARGETING THERAPY CURRENT MARKET TREND & DEVELOPMENTS

- 8.1 Current Market Outline
- 8.2 Future Market Forecast

9. FERROPTOSIS TARGETING THERAPY TREND ANALYSIS BY REGION

- 9.1 US
- 9.2 China
- 9.3 Europe
- 9.4 South Korea

10. FERROPTOSIS CANDIDATES GRANTED FDA & EMA DESIGNATIONS

11. COMBINATION STRATEGIES FOR FERROPTOSIS TARGETING THERAPIES

- 11.1 Combinations with Conventional Therapies
- 11.2 Combinations with Photodynamic Therapies & Magnetic Field

12. PLATFORMS USED FOR DEVELOPING ADVANCED FERROPTOSIS TARGETING THERAPY

- 12.1 Ferroptosis & Inflammation Platform

12.2 MIT Platform

12.3 Kojin Ferroptosis Platform

13. GLOBAL FERROPTOSIS TARGETING THERAPY MARKET DYNAMICS

13.1 Market Drivers

13.2 Market Challenges

14. COMPETITIVE LANDSCAPE

14.1 Kojin Therapeutics

14.2 MitolImmune Therapeutics

14.3 Prothegen

14.4 PTC Therapeutics

14.5 Sumitomo

14.6 Tharimmune

Figure 1-1: Role of Ferroptosis in Various Indications

Figure 1-2: Progression of Cell Death

Figure 2-1: Need of Ferroptosis Therapy

Figure 3-1: Ferroptosis Related Protein as Diagnostic & Prognostic Marker

Figure 4-1: Therapeutic Modality for Ferroptosis

Figure 5-1: Plant Products Used to Induce Ferroptosis in Cancer Treatment

Figure 5-2: CNSI-Fe (II) Phase I Study – Initiation & Completion Year

Figure 5-3: N6F11 (Ferroptosis Inducer) – Mode of Action

Figure 5-4: MIT-001 Phase II (NCT05493800) Study – Initiation & Completion Year

Figure 5-5: MIT-001 – Preclinical Stage for Viral Infections

Figure 5-6: Vatiquinone (NCT05515536) Phase III Study – Initiation & Completion Year

Figure 5-7: Utreloxastat Phase II Study – Initiation & Completion Year

Figure 6-1: Global – Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2024

Figure 6-2: Global – Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2024 - 2030

Figure 6-3: Global – Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2024

Figure 6-4: Global – Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2024 - 2030

Figure 6-5: Global – Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2024

Figure 8-1: Key Players – Ferroptosis

Figure 8-2: Rudolf Virchow Centre & Julius-Maximilians-Universität Würzburg Professors received Grant by European Research Council

Figure 8-3: Ferroptosis – Future Market

Figure 9-1: Vatiquinone Phase III (NCT05218655) Study – Initiation & Completion Year

Figure 9-2: Utreloxastat & Vatiquinone Current Development Status

Figure 9-3: Kojin Therapeutics Investors

Figure 9-4: Roche Accelerator, China - Included Keen Therapeutics to Advance Ferroptosis Therapies

Figure 9-5: MIT-001 Phase II (NCT04651634) Study – Initiation & Completion Year

Figure 11-1: Ferroptosis Combinations with Other Therapies

Figure 12-1: Kojin Therapeutics - Ferroptosis Platform

Figure 13-1: Ferroptosis – Market Drivers

Figure 13-2: Ferroptosis – Market Challenges

Table 4-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis

Table 5-1: Reversing Therapies Resistance by Ferroptosis Inducing Compounds for Cancer

Table 5-2: Role of Ferroptosis in Autoimmune & Inflammatory Disease

Table 5-3: Anti-Ferroptosis Therapeutic Options for Autoimmune & Inflammatory Disease

Table 5-4: Ferroptosis Effector & its Mechanism in Nervous System Disorders

Table 5-5: Role of Ferroptosis in Cardiovascular Diseases

Table 10-1: Ferroptosis Targeting Therapies Granted FDA & EMA Designations

I would like to order

Product name: Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024

Product link: <https://marketpublishers.com/r/GB7B377CAF0DEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB7B377CAF0DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970